- Conditions
- Age-Related Macular Degeneration
- Interventions
- Squalamine Lactate Ophthalmic Solution, 0.2%, Placebo Ophthalmic Solution, ranibizumab
- Drug
- Lead sponsor
- Ohr Pharmaceutical Inc.
- Industry
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • Hagerstown, Maryland • New York, New York + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2209–2232
of 8,381
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Osteoporosis, Renal Osteodystrophy, Kidney Transplant; Complications
- Interventions
- Denosumab Inj 60 mg/ml, Placebo
- Drug · Other
- Lead sponsor
- Thomas Nickolas, MD MS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Evanston, Illinois • New York, New York
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- Phesgo, Giredestrant, Docetaxel, Paclitaxel, LHRH Agonist, Optional Endocrine Therapy of Investigator's Choice
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 922 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 7 more
- Conditions
- Hyper Bilirubinemia, Premature Infant
- Interventions
- Phototherapy lights
- Device
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 22 Weeks to 27 Weeks
- Enrollment
- 1,700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more
- Conditions
- Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
- Interventions
- Gevokizumab, Bevacizumab, Modified FOLFOX6, FOLFIRI, Ramucirumab, Paclitaxel, Cabozantinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- Los Angeles, California • St Louis, Missouri • Nashville, Tennessee
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- MEK162, Panitumumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New York, New York
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer, Prostate Cancer
- Interventions
- MDX-1106
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Detroit, Michigan • St Louis, Missouri + 1 more
- Conditions
- Breast Cancer
- Interventions
- HD PET/CT
- Diagnostic Test
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Lymphoma
- Interventions
- Rituxan, BEAM, Autologous stem cell transplant
- Drug · Procedure
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2009
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), T-cell Lymphoma (PTCL and CTCL), B-cell Non Hodgkin Lymphoma (NHL)
- Interventions
- Cerdulatinib, Rituximab
- Drug · Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 23
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Los Angeles, California + 20 more
- Conditions
- Ovarian Neoplasms
- Interventions
- Niraparib, TSR-042, Bevacizumab, Carboplatin, Paclitaxel
- Drug · Biological
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
- Drug · Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 58 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma
- Interventions
- Cetuximab, Laboratory Biomarker Analysis, Tivantinib
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 24
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 19 more
- Conditions
- Peer Review, Research
- Interventions
- Duragesic reference fentanyl TDS, Apotex generic fentanyl TDS, Mylan generic fentanyl TDS
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Peritoneal Cancer
- Interventions
- Bevacizumab, Oxaliplatin, Paclitaxel
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Severe Aplastic Anemia (SAA)
- Interventions
- antithymocyte globulin, cyclophosphamide, cyclosporine
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 15 Years to 110 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Dense Breasts
- Interventions
- Denosumab, Placebo, Calcium, Vitamin D3, Core needle biopsy, Blood draw
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- Brentuximab vedotin, Lenalidomide
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Columbus, Ohio
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma
- Interventions
- Cetuximab, Questionnaire administration, Quality of life assessment
- Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Nivolumab, Albumin-bound paclitaxel, Paricalcitol, Cisplatin, Gemcitabine
- Drug
- Lead sponsor
- HonorHealth Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Colorectal Cancer
- Interventions
- bevacizumab, capecitabine, fluorouracil, leucovorin calcium, oxaliplatin
- Biological · Drug
- Lead sponsor
- Prologue Research International
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Greenbrae, California + 47 more
- Conditions
- Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Cabozantinib, Ipilimumab, Nivolumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 468
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Jonesboro, Arkansas + 301 more
- Conditions
- Metastatic Melanoma
- Interventions
- Ipilimumab, Tumor Infiltrating Lymphocytes (TIL), Administration of Lymphodepletion, Cyclophosphamide as Part of Lymphodepletion, Fludarabine as Part of Lymphodepletion, High Dose IL-2, Adoptive Cell Therapy with TIL
- Drug · Procedure · Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Breast Neoplasms, HER2/Neu Positive, Geriatric Health Services
- Interventions
- Lapatinib, Trastuzumab, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 8
- States / cities
- Duarte, California • Lancaster, California • Pasadena, California + 5 more